{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-071516","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.553418+00:00","generated_at":"2026-05-16T00:06:16.387220+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"RxSight reports Q4 revenue down 19% YoY; 2025 net loss $(38.9M); issues weak 2026 guidance","bullets":["Q4 2025 revenue $32.6M (-19% YoY); LAL revenue -1%, LDD revenue -72%.","FY 2025 revenue $134.5M (-4% YoY); net loss $(38.9M) vs $(27.5M) in 2024.","LAL unit sales 109,615 (+12% YoY); LDD installed base 1,134 units; procedures >300,000 since launch.","FY 2026 guidance: revenue $120-135M (down YoY); gross margin 70-72%; op-ex $150-160M.","Adjusted net loss per share $(0.18) in FY 2025 vs $(0.07) in FY 2024; cash $228.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-071516","json":"https://secwatch.observer/filing/0001193125-26-071516.json","markdown":"https://secwatch.observer/filing/0001193125-26-071516.md","text":"https://secwatch.observer/filing/0001193125-26-071516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000119312526071516/0001193125-26-071516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000119312526071516/rxst-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:06:16.387220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}